Healthcare and Pharmaceuticals

Following a tireless campaign by cancer patients, doctors and campaigners, the breast cancer drug Kadcyla has been re-listed on the UK’s Cancer Drug Fund (CDF) List and will remain available to terminal patients suffering with HER2-positive tumours for whom the medicine Herceptin no longer works. The pharmaceutical firm Roche’s Kadcyla drug is proven to prolong…